Prevention for Prenatal Health: the Health in Pregnancy (HIP) Study
Pregnancy is a critical time to address preventable behavioral risks that pose serious threats to the health of both the mother and the developing fetus. We propose to conduct a randomized, controlled trial to determine the extent to which the Health in Pregnancy (HIP) program, a brief motivational intervention featuring a “Video Doctor,” provider cueing sheets, and patient educational worksheets, can reduce pregnant women’s cigarette smoking, alcohol drinking, illicit drug use, and domestic violence risks compared with usual care.
Description
Regular prenatal visits offer opportunities to deliver and reinforce risk reduction messages regarding tobacco, alcohol, or illicit drug use and domestic violence. Because health care providers may lack the time, comfort, or skills to screen or counsel their patients about these risks, innovative approaches are needed. Computer programs are increasingly used to assess risky behaviors and deliver individualized preventive interventions. We have designed a randomized, controlled trial to determine if a brief, interactive, multimedia intervention delivered on a laptop computer and integrated into routine prenatal care can reduce pregnant women’s smoking, drinking, drug use, and experiences of domestic violence compared to usual care. To capitalize on health care providers’ credibility, the multimedia intervention is delivered by an actor-portrayed “Video Doctor” programmed to respond to participant input, simulating a live interview. Pregnant women who receive prenatal care at one of the study sites and who consent to participate will be screened for substance use and domestic violence prior to a regularly scheduled medical appointment. Women who report one or more of these risks will be randomly assigned to the Intervention or Control group according to a blocked, stratified randomization plan. Participants in the Intervention group will receive the Health in Pregnancy (HIP) intervention, consisting of brief, multimedia counseling presented by a “Video Doctor” and an educational worksheet. Their provider will receive a “Cueing Sheet,” which offers a brief summary of the patient’s risk profile and suggests counseling statements. Components of the multimedia program will be tailored to each participant’s risk profile and readiness to change. Women assigned to the Control group will complete a risk assessment than receive the usual care offered by the health care settings. Both Intervention and Control participants will complete two follow-up risk assessments at consecutive medical visits approximately four weeks apart. At the first follow-up session, Intervention participants will also receive “booster” risk reduction messages from teh video doctor. To determine the effect of the HIP program on patient-provider discussions, both Intervention and Control participants will complete a post-interview after their medical appointment. The post-interview will also assess the acceptability of the HIP program by participants. To determine the effect of teh program on participants’ risky behaviors we will compare self-reported discussions, behavior change, and readiness to change at baseline and at a third session with the computer program. We expect that participants in the Intervention group will show significant reductions in risky behaviors compared to the Control group.
Status: Recruiting (N/A). Started on June 1st, 2006. Ended on December 1st, 2007.
Enrollment: 450 subjects
Study Type: Interventional
Study Design:
- Prevention
- Randomized
- Single Blind (Subject)
- Placebo Control
- Parallel Assignment
- Efficacy Study
Conditions:
Interventions:
- Behavioral: HIP
Eligibility
Inclusion Criteria:
Age 18 or older
English speaking
Pregnant and receiving prenatal care at a participating study site.
Exclusion Criteria:
- >25 weeks gestation at baseline session.
- Gender
Female
- Mininum Age
18 Years
- Maximum Age
N/A
- Healthy Volunteers
Accepts Healthy Volunteers
Resources
Source: National Institute on Drug Abuse (NIDA)
Authority: United States: Institutional Review Board
Locations
-
San Francisco General Hospital
San Francisco
California
94110
United States
-
Santa Clara Valley Medical Center
San Jose
California
95128
United States
-
UCSF Faculty Obstetrics and Gynecology Group
San Francisco
California
94143
United States
-
Highland Hospital
Oakland
California
94602
United States
-
St. Luke's Hospital
San Francisco
California
94110
United States
Officials
Barbara Gerbert, PhD (Principal Investigator, University of California, San Francisco)
Rebecca Jackson, MD (Study Director, San Francisco General Hospital)
Sponsors
National Institute on Drug Abuse (NIDA) (Lead Sponsor)
References
None.
Links
- Date Verified
- October 1st, 2007
- First Received
- October 5th, 2007
- Last Changed
- October 5th, 2007
Information obtained from ClinicalTrials.gov on July 15, 2008. Link to the current ClinicalTrials.gov record.
All data in the Healia Clinical Trials Information Database and content displayed by the Healia Clinical Trials Search Engine are licensed from the National Institutes of Health (National Library of Medicine), which collects and maintains the data.
The Healia Clinical Trials Search Engine searches the data set at clinicaltrials.gov, providing up-to-date information about current clinical trials. In the Healia Clinical Trials Database you can find information on new experimental drugs, medical devices, and other types of treatments for all types of diseases. Each clinical trial description includes information about the phase of the trial (phase I, phase II, or phase III), the trial’s methods, such as whether it is a randomized, placebo controlled, double blind study, and the status of the trial including whether or not the trial is currently enrolling new participants.
